<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652271</url>
  </required_header>
  <id_info>
    <org_study_id>20203109-PG</org_study_id>
    <nct_id>NCT04652271</nct_id>
  </id_info>
  <brief_title>International Pancreatic Surgery Outcomes Study - PancreasGroup.Org</brief_title>
  <official_title>PancreasGroup.Org - International Pancreatic Surgery Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Free Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Snapshot&quot; study worldwide over 3 months in 2021. Provide a verified record of true morbidity&#xD;
      and mortality. Identify modifiable predicting factors of outcome. Obtain PubMed citable&#xD;
      co-authorship,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PancreasGroup.org team is conducting a &quot;snapshot&quot; clinical study investigating the&#xD;
      outcomes of pancreatic surgery worldwide. This &quot;collaborative&quot; model for snapshot clinical&#xD;
      studies is a well-established approach for assessing current practice in a short period of&#xD;
      time.&#xD;
&#xD;
      There will be 3 months of prospective enrolment and 3 months follow up within a 12-month&#xD;
      frame. The study will provide highly valuable data on outcomes after pancreatic surgery.&#xD;
&#xD;
      The investigators are aiming at providing a verified record of true morbidity and mortality&#xD;
      in consecutive unselected patients. This way the investigators will help identify relevant,&#xD;
      modifiable predicting factors for outcome after pancreatic surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Postoperative death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Postoperative complication rates classified according to Clavien-Dindo</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Patients undergoing pancreatic surgery</arm_group_label>
    <description>Patients undergoing any type of pancreatic surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic surgery</intervention_name>
    <description>Open, laparoscopic or robotic surgery of the pancreas</description>
    <arm_group_label>Patients undergoing pancreatic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients undergoing pancreatic resection by surgeons at their respective centres&#xD;
        are eligible for study inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All indications (including benign and malignant)&#xD;
&#xD;
          -  Open, laparoscopic or robotic.&#xD;
&#xD;
          -  Elective or emergency.&#xD;
&#xD;
          -  Partial or total pancreatectomies.&#xD;
&#xD;
          -  Pancreatic tumour enucleations.&#xD;
&#xD;
          -  Procedures with concomitant vascular or other organ resections.&#xD;
&#xD;
          -  Pancreatic duct drainage procedures (e.g. Frey, Puestow, or Beger)&#xD;
&#xD;
          -  Adults 18 years of age or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pancreas or islet cell transplantation.&#xD;
&#xD;
          -  Transcutaneous or transgastric imaging-guided ablation (e.g. RFA) or electroporation&#xD;
             (e.g. NanoKnife).&#xD;
&#xD;
          -  Endoscopic (e.g. endoscopic retrograde cholangiopancreatography, stent or lithotripsy)&#xD;
             procedures.&#xD;
&#xD;
          -  Endoscopic transgastric and surgical necrosectomies excluded.&#xD;
&#xD;
          -  Patients less than 18 years of age excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiseppe K Fusai, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Free Hospital London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Ferrone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital, Boston, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitri A Raptis, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital London, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiseppe K Fusai, MD, MS</last_name>
    <phone>+442077940500</phone>
    <email>g.fusai@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dimitri A Raptis, MD, MSc, PhD</last_name>
    <phone>+447584560889</phone>
    <email>dimitri.raptis@nhs.net</email>
  </overall_contact_backup>
  <link>
    <url>https://pancreasgroup.org/</url>
    <description>The official website of PancreasGroup.org</description>
  </link>
  <link>
    <url>https://rbiostatistics.com</url>
    <description>The R statistical package for analysis</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic surgery</keyword>
  <keyword>snapshot</keyword>
  <keyword>global surgery</keyword>
  <keyword>predictors</keyword>
  <keyword>outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>PancreasGroup.org is a collaboration of all surgeons contributing data as equal partners. Each surgeon contributing data has access to analysis files of the entire database at any time point and the right to propose analyses and publish data as long as every surgeon contributing data are included as a group author in every publication and have an opportunity to review the data prior to submission. Each collaborator has access to their own data in a form of excel export file without requiring permission or approval by the PancreasGroup.org management committee.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available after the first and main publication of PancreasGroup.org. They will be available for at least 10 years.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

